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Abstract: Fatty acid oxidation (FAO) produces the majority of ATP 
used to sustain the cardiac contractile work, while glycolysis is a 
secondary source of ATP under normal physiological conditions. 
FAO impairment has been reported in the advanced stages of Heart 
Failure (HF) and is strongly linked to disease progression and 
severity. Thus, from a clinical perspective, FAO dysregulation 
provides prognostic value for HF progression, whose assessment 
could be used to improve patients’ monitoring and therapy 
effectiveness. Positron emission tomography (PET) imaging 
represents a powerful tool for the assessment and quantification of 
metabolic pathways, in vivo. Several FAO PET tracers have been 
reported in the literature but none of them is in routine clinical use 
yet. Metabolically trapped tracers are particularly interesting, 
because they undergo FAO generating a radioactive metabolite, 
which is subsequently trapped in the mitochondria, thus providing a 
quantitative means of measuring FAO in vivo. Herein we describe 
the design, synthesis, tritium labelling and radiofluorination of 4,4,16-
trifluoro-palmitate 1 as a novel potential metabolically trapped FAO 
tracer. Preliminary PET-CT studies on [18F]1 in rats showed rapid 
blood clearance, good metabolic stability – confirmed using [3H]1 in 
vitro – and resistance towards defluorination. However, cardiac 
uptake in rats was modest (0.24 ± 0.04% ID/g) and kinetic analysis 
showed reversible uptake, indicating that [18F]1 is not irreversibly 
trapped. 
Introduction 
Heart failure (HF) is a complex pathology that results from any 
structural or functional impairment of ventricular filling or ejection 
of blood[1]. During HF the cardiac pump function is unable to 
meet the body’s needs and guarantee the optimal perfusion of 
tissues. It affects at least 26 million people worldwide[2]  and 
depends on a variety of factors including aetiology, underlying 
coronary disease, and the presence of comorbidities such as 
obesity, hypertension and diabetes. There is no specific 
diagnostic test for HF and the diagnosis is based on a thorough 
clinical examination of the patient’s clinical history and 
symptoms[3]. 
Adenosine triphosphate (ATP) is the main chemical fuel required 
for the contraction of the heart, which is strongly energy-
demanding and continually requires ATP to sustain the 
contractile function. In the healthy heart, in normoxic conditions, 
almost 95% of ATP is produced through mitochondrial oxidative 
phosphorylation, with the remainder originating from glycolysis 
and the tricarboxylic acid (TCA) cycle[4]. The latter is fuelled by 
acetyl-CoA derived from glucose oxidation or from fatty acid β-
oxidation (FAO), which accounts for at least 70% of the ATP 
production in the healthy adult heart. [5–7]  
FAO is a highly regulated process that ultimately metabolises 
FAs in the mitochondrial matrix. Myocardial FAO can be 
influenced by many factors, such as the concentration of free 
FAs in plasma, hormonal status, oxygen availability and energy 
demand. The overall FAO rate depends on a multitude of 
processes, including FAs uptake into myocardium mediated by 
the FA transporter CD36, activation to corresponding thioesters 
by fatty acyl-CoA synthetase, incorporation in the intracardiac 
lipid pool by esterification, mitochondrial import by carnitine 
palmitoyltransferase I/II and carnitine acyltranslocase (CPT-
I/CPT-II and CAT) and the four enzymes involved in the β-
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CPT-I inhibitors, such as etomoxir or POCA (sodium 2-[5-(4-
chlorophenyl)-pentyl]-oxirane-2-carboxylate), have been widely 
employed to reduce FAO rates in experimental studies.[9–12]. 
Analysis of data from HF patients proved to be challenging due 
to the diverse aetiology of the syndrome, concomitant 
comorbidities, numerous pharmacological therapies and clinical 
stage. Despite these difficulties, it is widely accepted that FAO 
decreases during HF progression and in late-stage HF[3,4,13–17], 
and one approach to investigate FAO non-invasively is by using 
positron emission tomography (PET). Contrary to other 
molecular imaging modalities, PET offers superb sensitivity and 
unlimited tissue penetration, and is fully quantitative and 
translational. Additionally, the administration of sub-
pharmacological doses (sub-nanomolar range) of the contrast 
agent (radiotracer) suffices to acquire high quality images, 
thereby minimising the risk of toxic effects and avoiding 




Figure 1. Examples of FAO tracers. 
 
Myocardial FAO PET imaging has shown great potential in 
patients with ischemic heart disease, cardiomyopathies and 
heart failure[21,22], because it allows the assessment and 
quantification of regional tissue function in vivo, which usually 
precedes any anatomical changes during disease progression. 
[11C]Palmitate (Fig. 1) has been extensively studied to monitor 
changes in metabolism in response to physiologic and 
pathologic conditions[23–27]. Complex mathematical modelling 
allows the estimation of tracer’s uptake, oxidation and 
esterification[28]; however, quantitation in ischemic myocardium 
is not possible with this probe[29]. Long-chain FAs such as 
[18F]FHDA and [18F]FHA have also been developed, but the 
complex metabolic handling of these analogues, along with their 
in vivo defluorination, complicates the development of modelling 
strategies[30]. To simplify the myocardial kinetics, metabolically 
trapped probes have been developed. These compounds were 
designed so that they could be retained in the myocardium 
exclusively as metabolites formed due to β-oxidation, allowing 
for a close relationship between trapping rate and FAO rate. 
[11C]BMHDA[31], [18F]3-MFHA and [18F]5-MFHA[32] are FA 
analogues with a methyl branch which have been designed to 
inhibit the β-oxidation cycle. However, these probes are poorly 
oxidised while being mainly incorporated into the intracardiac 
lipid pool, thus limiting their application as FAO tracers[22]. Fatty 
acids incorporating sulphur atoms have also been reported as 
metabolically trapped probes. [18F]FTHA showed prolonged 
myocardial retention and FAO inhibition with a CPT-I inhibitor 
caused an 81% reduction in murine heart uptake, indicating 
specificity as FAO substrate[10]. However, this tracer has not 
been validated in the hypoxic myocardium, suggesting that FAO 
is not solely responsible for its accumulation[33]. [18F]FTP showed 
specificity as β-oxidation substrate in normal and hypoxic 
perfused rat heart, despite suboptimal retention and high bone 
uptake, indicating extensive defluorination[34]. [18F]FTO has been 
later reported with improved cardiac retention, even though the 
exact identity of the trapped metabolites is still unclear[9]. 
Additionally, compounds incorporating fluorine atoms or a 
cyclopropyl group have been reported in the literature[35,36], but 
their specificity for the FAO pathway still has to be clarified. 
Herein we report the synthesis, tritium labelling, 18F-labelling and 
preclinical evaluation of 4,4,16-trifluoro-palmitate (see Scheme 
1), a novel FAO PET tracer candidate for cardiac imaging. The 
18F-labelled compound, [18F]1, constitutes a fatty acid analogue 
with a [18F]fluorine nuclide in -position and a geminal 
[19F]difluoro group in position 4 of the hydrocarbon chain. These 
structural properties were carefully designed for the tracer to be 
taken up by the myocardium as a conventional fatty acid, e.g. as 
a FAO substrate. As shown in Fig. 2, the β-oxidation cycle was 
then expected to generate a reactive difluoroketone which would 
be trapped inside the mitochondria; hence, its accumulation 
would reflect the FAO rate. Difluoroketones can behave as 
transition state mimics and have been reported as enzymatic 
inhibitors, owing to the unique capability of binding in a 
substrate-like fashion in pockets on both sides of an enzyme’s 
catalytic residues[37]. Additionally, the electrophilicity of the 
ketone carbonyl group is enhanced by the strong inductive effect 
of fluorine on the adjacent carbon atom[38], thus increasing the 
susceptibility to nucleophilic attack by mitochondrial enzymes 
and aminoacidic residues.  
 
Figure 2. Working hypothesis of metabolic trapping of the PET tracer 
candidate [18F]1. β-Oxidation metabolism was expected to generate a 
difluoroketone by sequential elimination, hydration and oxidation to 
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Results and Discussion 
CHEMISTRY 
 
Synthesis of tritium labelling precursor 10 and non-
radioactive tracer [19F]1 
Tritium labelling is an invaluable tool for performing preliminary 
in vitro studies on candidate PET tracers[39]. Since labelling with 
tritium can be readily performed by reduction of unsaturated 
hydrocarbons[40], we designed and synthesised compound 10 – 
which incorporates a double bond that can be tritiated by 
palladium-catalysed reduction with T2 (Scheme 1) Additionally, 
the same synthetic route allowed us to prepare the non-
radioactive version of the tracer [19F]1, which was used as a 
reference for confirming the identity of the tracer [18F]1 by high 
performance liquid chromatography (HPLC). Several 
unsuccessful approaches to these compounds are described in 
the Supporting Information.  
 
 
Scheme 1. Synthesis of compounds [19F]1 and 10. Reagents and conditions: 
(i) NaI, acetone, reflux, 24 h; (ii) CuI, HMPA, P(OEt)3, THF, -40 °C 1 h, 12 h rt; 
(iii) DAST, DCM, -30 °C 1 h, 12 h rt; (iv) BrCF2CO2Et, CuI, PMDETA, ACN, 
100 °C, 12 h; (v) NaBH4, EtOH, 2 h; (vi) oxalyl chloride, DMSO, TEA, DCM, -
50 °C to rt, 1 h; (vii) BrCH2CO2Et, Zn, TMSCl, THF, reflux, 1 h; (viii) MsCl, TEA, 
DCM, 12 h, then DBU, 2 h; (ix) [(C6H5)3PCuH]6, toluene, 12 h; (x) H2, Pd/C, 
MeOH, 12 h; (xi); LiOH, THF/H2O 1:1; 12 h. 
 
The preparation of the target compounds [19F]1 and 10 could be 
achieved via a multi-step process. First, commercially available 
10-bromo-1-decanol was converted to the corresponding iodide 
2 via a Finkelstein reaction following a published protocol[41]. 
Compound 2 was then treated with vinylmagnesium bromide to 
give 3, which was deoxofluorinated with diethylaminosulfur 
trifluoride (DAST). The resulting terminal olefin 4 was submitted 
to difluoroalkylation with ethyl bromodifluoroacetate according to 
the methodology reported by Wang et al[42], yielding the key 
unsaturated ester 5 as 5:1 E/Z mixture of stereoisomers, as 
determined by NMR (see Experimental section). The 
intermediate aldehyde 7 was required as substrate for the 
subsequent Reformatsky reaction, but direct reduction of 5 to 7 
with diisobutyl auminum hydride (DIBAL-H) was unsuccessful. 
However, this problem could be circumvented by full reduction to 
alcohol 6 with NaBH4, followed by Swern oxidation to 7. 
Reformatsky reaction with bromoacetate afforded the desired β-
hydroxy ester 8. Disappointingly, a variety of methods to directly 
deoxygenate 8 led to substrate decomposition, including Barton-
McCombie deoxygenation with tributyltin hydride/ 
azobisisobutyronitrile (AIBN)[43], with 
triethylborane/diphenylsilane[44] or with indium chloride[45]. 
However, we observed that a stored batch of pure 
thiocarbonylimidazole xanthate derivative of 8, synthesised for 
attempting a Barton-McCombie deoxygenation, spontaneously 
underwent elimination to the corresponding α,β-unsaturated 
derivative 9 upon storage at 10 °C. Thus, 8 was dehydrated by 
one-pot mesylation/elimination, affording the key intermediate 9. 
Full hydrogenation of 9 followed by basic hydrolysis of the ethyl 
ester 9a yielded the non-radioactive tracer [19F]1, while its 
selective 1,4-conjugate reduction with the Stryker’s reagent[46] 
afforded the tritium labelling precursor 10 as a 5:1 E/Z mixture of 
stereoisomers, as determined by NMR. Unexpectedly, 
hydrogenation of 9 using Pd/C in methanol afforded a mixture of 
desired compound 1 and 4,16-difluoropalmitate, which could be 
separated by supercritical fluid chromatography (SFC). It was 
later found that hydrogenation in THF completely suppressed 
the defluorination side-reaction.  
 
Synthesis of fluorine labelling precursor 18 
Fluorine-18 is commonly introduced in organic molecules by 
displacement of a good leaving group, such as a tosylate or a 
mesylate[47], by [18F]fluoride. Thus, tosylate derivative 18 was 
identified as suitable fluorine labelling precursor, and 
successfully synthesised as shown in Scheme 2. Unsuccessful 
synthetic routes towards compound 18 are described in the 
Supporting Information. 
 
Scheme 2. Fluorine labelling precursor synthesis. Reagents and conditions: (i) 
BzCl, DMAP, pyridine, DCM, 1 h; (ii) BrCF2CO2Et, CuI, PMDETA, ACN, 
100 °C, 12 h; (iii) H2, Pd/C, THF, 12 h; (iv) NaBH4, EtOH, 1 h; (v) oxalyl 
chloride, DMSO, TEA, DCM, -50 °C to rt, 1 h; (vi) BrCH2CO2Et, Zn, TMSCl, 
THF, reflux, 1 h; (vii) MsCl, TEA, DCM, 12 h, then DBU, 2 h; (viii) H2, Pd/C, 
THF, 1 h; (ix) NaOEt, EtOH, 12 h; (x) TsCl, pyridine, DMAP, DCM, 12 h. 
 
The unsaturated alcohol 3 was protected as benzoyl ester and 
successfully coupled with ethyl bromodifluoroacetate, affording 
ester 12 as a 5:1 mixture of E/Z stereoisomers. In analogy with 
the chemistry shown in Scheme 1, 12 was hydrogenated to 13, 
which was reduced to 14 with NaBH4 and used in a Reformatsky 
reaction with ethyl bromoacetate to afford 15. The resulting 
secondary alcohol function was dehydroxylated in two steps to 
16, whose -hydroxy group was deprotected to give 17. Finally, 
tosylation under standard conditions afforded the 
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Radiosynthesis of [3H]1 
A tritium labelled version of compound 1 was successfully 
prepared with the view of performing a preliminary in vitro 
evaluation of the tracer. With that aim, compound 10 was treated 
with tritium gas and 10% Pd/C as catalyst in THF (see Fehler! 
Verweisquelle konnte nicht gefunden werden.) to afford 
tritiated ethyl 4,4,16-palmitate, which was isolated by HPLC in 
98.6% radiochemical purity. Subsequent basic hydrolysis of the 
ester function and HPLC purification afforded [3H]1 as a 36.7 
MBq/mL solution in acetonitrile, with radiochemical purity higher 
than 99%. 
 
Scheme 3. Radiosynthesis of [3H]1. Reagents and conditions: (i) 3H2, 10% 
Pd/C, THF; (ii) LiOH, THF/H2O. 
 
The molar activity of [3H]1 was determined by NMR, according to 
the method of Schenk et al.[48], because its mass spectrum 
showed numerous isotopologues, suggesting that tritium 
incorporation had occurred in at least four positions of the 
molecule. This led to a mass spectrum which contained multiple 
overlapping isotopic patterns and any attempt to utilize this for 
determination of molar activity would have been accompanied 
by a large error[49].  The lack of a substantial UV chromophore 
negated the use of a standard mode of molar activity 
determination. Therefore, molar activity calculation by NMR 
using an internal standard seemed the best option and tritiated 
canagliflozin (1.3 Gbq/mmol molar activity, 91.7% radiochemical 
purity) was employed as internal standard. The method relied on 
the acquisition of 1H and 3H NMR spectra of a sample containing 
known amounts of [3H]1 and [3H]canagliflozin; the molar activity 
was then calculated by comparison of 1H and 3H integrals of the 
two compounds.  
A preliminary experiment was undertaken with the non-tritiated 
compounds dissolved in CD3OD (Fig. 3). The resonances of two 
of the canagliflozin aromatic protons at 7.56 ppm and 
fluoromethylene doublets of triplets signal at 4.42 ppm of 1 were 
deemed to be ideal for the purpose because they are widely 
separated, well resolved and, importantly, not overlapping with 
the solvent signals. Moreover, the two canagliflozin thiophene 
ring tritium atoms (7.18 ppm, 6.77 ppm) are convenient for 3H 
NMR comparison because they are well separated from the 
analyte aliphatic resonances (1.5 ppm).  
Encouraged by these findings, carefully measured 100 MBq of 
standard and analyte were dissolved in deuterated methanol 
and 1H/3H NMR spectra were acquired (Fig. 4). Finally, integrals 
were compared as reported by Schenk et al.[48] and the 
calculated molar activity was found to be 2730 GBq/mmol. This 
result exceeded the maximum theoretical molar activity 
calculated for two tritium atoms (2131 GBq/mmol) and was 




Figure 3. 1H NMR spectra of 1 and canagliflozin in CD3OD. Experiment 1 (bottom, red line) shows the fluoromethylene doublets of triplets signal of 1 (4.42 ppm). 















This article is protected by copyright. All rights reserved.




Figure 4. Proton decoupled 3H NMR of [3H]1 and [3H]Canagliflozin in CD3OD. Aromatic signals for labelled canagliflozin are visible at 6.77 and 7.18 ppm. 
Aliphatic signals for [3H]1 are shown at 1.46 – 1.28 ppm. 
 
In vitro metabolism 
The tritium labelled compound was used to investigate 
hydroxylation metabolism, a minor metabolic pathway which has 
been described as being NADPH- dependent and catalyzed by 
the microsomal P450 enzyme family[50]. Experimentally, rat liver 
microsomes (ThermoFisher Scientific; 0.1mg of protein) were 
incubated with [3H]1 (0.36 MBq; 13 nmol) in the presence of 
NADPH as the cofactor, and the mixture was analyzed by radio-
HPLC at 15, 30, 60, and 120 min. Initially, one major peak in the 
chromatogram was identified as [3H]1, proving the radiochemical 
purity of the tracer. The appearance of a broad peak in the 
chromatogram with lower retention time at 15 min of incubation 
(Fig. 5.) confirmed the presence of metabolism. The percentage 
of the non-metabolized [3H]1 progressively decreased with 
incubation time, to reach values of ca. 25% at 2 hours of 
incubation (Fig. 5). The identity of the metabolites could not be 
confirmed. Cytochrome P450 enzymes are selective for C-H 
functionalization[51], hence the presence of free [18F]fluoride due 
to fluorine-by-hydroxyl exchange can be excluded. Previous 
works reported in the literature have demonstrated that the 
presence of fluorine atoms in ω-position favour hydroxylation at 
the ω-3, ω-2 and ω-1 positions[52]. Hence, we hypothesize a 
major contribution of these hydroxylated metabolites.  
Considering the values obtained at t=15 min of incubation, the 
initial metabolism rate was calculated to be 3.1 nmol/(mg min). It 
has been proven that the presence of fluorine atoms in ω-
position stabilize the transition states of the hydroxylation 
reaction and therefore enhance reaction rates[51]. However, our 
values are in the range of those reported in the literature for 
lauric and oleic acid[50] under equivalent experimental conditions. 
Fitting of a mono-exponential curve to the experimental data 
showed the presence of a plateau, suggesting that a fraction of 
the fatty acid remains unchanged even at very long incubation 
times.    
 
Figure 5. a) Chromatographic profiles obtained for [3H]1 at different times after 
incubation with rat liver microsomes in the presence of NADPH. The peak 
corresponding to the metabolites is indicated with a green arrow; b) 
percentage of non-metabolised [3H]1 as determined by integration of the area 
under the peaks in (a). In red, a mono-exponential equation fitted to the 
experimental data. 
 
Radiosynthesis of [18F]1 
Further development of 1 into a tracer for in vivo PET imaging 
experiments required the incorporation of a positron emitter in -
position. Hence, we next tackled the radiosynthesis of [18F]1, 
which was achieved following a two-step process: [18F]fluoride 
nucleophilic displacement of tosylate 18 first, followed by ethyl 
ester hydrolysis. Typical conditions reported in the literature for 
the preparation of other 18F-labelled FAs involve heating the 
precursor and [18F]fluoride in acetonitrile or THF solution, 
followed by additional heating in the presence of hydrochloric 
acid or potassium hydroxide to hydrolyse the protecting groups 
[9,34,35]. In our case, compound 18 was successfully radiolabelled 
using K222 as the phase transfer catalyst and acetonitrile as the 
solvent (Scheme 4). After ester hydrolysis with aqueous 
potassium hydroxide, purification by HPLC (Fig. S1b) and 
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tracer in 10-15% decay corrected radiochemical yield in an 
overall synthesis time of 70 min. Radiochemical purity was 
above 99%, as determined by radio-HPLC (Fig. S1a).  
 
Scheme 4. Radiosynthesis of [18F]1. Reagents and conditions: (i) [18F]KF/K222, 
ACN, 90 °C, 15 minutes; (ii) KOH, 90 °C, 5 minutes. 
 
The radiotracer proved stable in physiological media, as 
determined by HPLC. Analysis at different times after incubation 
in the vehicle used for administration (1% bovine serum albumin 
–BSA– in physiological saline solution)[9,34] confirmed the 
presence of only one radioactive peak, corresponding to [18F]1, 
up to six hours of incubation (Fig. S2). 
 
IN VIVO STUDIES 
 
Blood clearance and in vivo metabolism 
New tracers require careful assessment of in vivo metabolism, 
as the formation of labelled metabolites complicates image 
interpretation and quantification[53]. Hence, we first explored 
blood clearance and tracer’s metabolism in vivo using an in-
house developed monitoring system (Fig. 6a) as previously 
described[54]. The system allows for the real-time determination 
of the concentration of radioactivity in arterial blood via 
extracorporeal circulation. Additionally, blood samples were 
withdrawn at preselected time points (5, 10, 15 and 30 minutes) 
for further processing.  
Experimentally, 21 ± 2 MBq of [18F]1 solution in ethanol/1% BSA 
in physiologic saline solution (1:9, v:v) were injected into rats 
(n=2) through the femoral vein, concomitantly with the start of 
radioactivity measurements, which was prolonged over 30 
minutes. Analysis of the withdrawn blood samples by HPLC 
showed excellent tracer metabolic stability in vivo, as no 
radioactive metabolites could be detected over the period 
studied (0-30 min; Fig. S3). Decay-corrected time activity curves 
(TACs) showed rapid clearance from the bloodstream at t<300 s 
(Fig. 6b). Interestingly, close-to-noise values were measured at 
t=450-900s, followed by an increase in radioactivity 
concentration at t>900 s which reached a maximum at t ~ 1300 
s. This trend, which can be clearly visualised when the Y axis is 
represented in logarithmic scale (Fig. 6b), is consistent with the 
presence of enterohepatic circulation (see below for further 
discussion). 
 
Figure 6. a) Schematic representation of the extracorporeal circulation system 
used for the determination of the arterial blood time-activity curve. Two 
catheters were inserted into the femoral artery and vein, respectively. The 
blood was pumped through a radioactive detector using a peristaltic pump. 
Blood samples were withdrawn at different time points to quantify the 
presence of metabolites; b) time-activity curves obtained after intravenous 
administration of [18F]1 in a healthy Sprague Dawley rat, expressed as a 
percentage of injected dose (%ID) per gram. Left: linear Y scale; right: 
logarithmic Y scale. 
 
Imaging studies 
To test whether [18F]1 would be subjected to oxidative metabolic 
trapping in the mitochondria in vivo, we decided to test whether 
etomoxir, a known CPT-I inhibitor, would cause any changes in 
the cardiac uptake of the tracer. We reasoned that if the tracer 
was a poor substrate for esterification and preferentially 
metabolized and retained in the mitochondria, a decreased 
retention of radioactivity upon pre-treatment with etomoxir would 
be observed.  
With that aim, biodistribution and heart uptake of [18F]1 were 
investigated by PET imaging in healthy rats, which were pre-
treated with etomoxir (n=5; “etomoxir” group) or the 
corresponding vehicle (n=5; “control” group) before tracer 
administration. Visual inspection of the images (Fig. 7a) showed 
the presence of the tracer in the blood pool at early time points 
after administration, and progressive accumulation of the 
radioactive signal in the liver (probably mediated by CD36, the 
physiological FA transporter) and in the gastrointestinal region, 
the latter more visible in the etomoxir pre-treated group. No 
accumulation of radioactivity was observed in bones, suggesting 
negligible in vivo defluorination, consistently with the excellent 
metabolic stability observed in metabolic in vivo studies.  
In order to acquire quantitative data, representative volumes of 
interest (VOIs) were delineated in selected organs (liver, lungs, 
and kidneys; Fig. 7b). The image corresponding to the first 
frame (0-0.1 min) and averaged image of the last frames (8.4-60 
min) enabled the delineation of VOIs in the caudal vena cava 
and the myocardium, respectively (Figure 7b). For all VOIs, the 
concentration of radioactivity as a function of time was 
determined (Fig. 7c). Consistently with the visual inspection of 
the images, a rapid accumulation of radioactivity was observed 
in the liver at early time points after administration, with a slightly 
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lungs and myocardium showed a high initial increase of 
radioactivity concentration (approx. 40 s after administration) 
followed by a fast clearance. Interestingly, a slight radioactivity 
increase was observed in these organs at late time points after 
tracer administration. However, this increase was more 
pronounced for control animals, and almost disappeared in the 
case of etomoxir-pre-treated animals. In line with results 
obtained by extracorporeal blood circulation, the image-derived 
blood TACs for control animals showed a fast peak at early time-
points, a rapid clearance phase and finally a slight increase 
which was sustained over time (t > 10 min). The ratio between 
the average concentration of radioactivity in blood (Cb) in the 
time frames 2-5 min and 15-60 min (Cp(2-5 min)/Cp(15-60 min)) was 
1.38 ± 0.11. This effect was not observed in etomoxir-treated 





Figure 7. a) PET images (coronal projections) obtained at different time points after administration of compound [18F]1 to rats pre-treated with vehicle (top) and 
etomoxir (bottom; dose = 40 mg/Kg). The images shown correspond to averaged frames in the indicated time-windows. PET images have been co-registered with 
representative CT slices for anatomical localization of the radioactive signal; b) representation of the volumes of interest (VOIs) drawn on the different organs to 
obtain dynamic time-activity curves; c) tracer time-activity curves in lungs, liver, blood, myocardium and kidneys, for animals pre-treated with vehicle (red; control 
group) and etomoxir (40 mg/Kg; blue;  etomoxir group). Data are presented as mean ± standard deviation, n = 3 per experimental scenario. 
 
The TAC profile observed in the blood from control animals and 
the accumulation of radioactivity in the liver observed at early 
time points, which suggest that the tracer is rapidly taken up by 
the hepatocytes, are compatible with in vitro metabolism results 
and the presence of enterohepatic circulation of [18F]1. We 
hypothesize that after liver uptake, part of the tracer undergoes 
hydroxylation metabolism. Part of the intact tracer is secreted 
into the bile and released in the intestine, where the activity is 
reabsorbed into the systemic circulation. This process is 
probably assisted by hepatic conjugation/intestinal 
deconjugation[55]. The absence of metabolites in plasma up to 
t=30 min after administration suggests that the fraction of 
compound [18F]1 that undergoes enterohepatic circulation is not 
metabolised in the liver, or forms a conjugate in the liver which, 
after deconjugation in the gastro-intestinal region, results in the 
release of intact radiotracer into the systemic circulation. In 
animals pre-treated with etomoxir, enterohepatic circulation was 
not observed. The reasons behind this finding remain unclear 
and will be investigated in future works.  
The rational design underlying the development of compound 
[18F]1 was to favour its metabolic trapping in the myocardium. 
Hence, TACs obtained in the myocardium were analysed using 
Patlak[56] graphical analysis (Fig. S4). However, the lack of a 
linear region suggested that the tracer is not irreversibly 
accumulated. Indeed, Logan analysis[57] of the cardiac TAC 
using the image-derived blood input function, showed profiles 
suggesting an equilibrium between the radioactivity in the heart 
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at equilibrium for control and etomoxir groups were 0.46 ± 0.11 
and 0.39 ± 0.12, respectively. The difference between groups 
was not statistically significant (P = 0.505), suggesting that [18F]1 
was not sensitive to FAO changes induced by etomoxir. 
 
 
Figure 8. Representative Logan plots (myocardium) corresponding to the 
control group (left) and etomoxir group (right). In both cases, the plot was 
created using the image-derived blood input function. The points used for the 
linear regression are shown as coloured dots. T* = 20 minutes. 
 
The similar cardiac accumulation observed between control and 
etomoxir group suggests that the tracer accumulation is not 
associated with β-oxidation processes. However, the reason 
behind the lack of differences between groups remains 
unresolved. This aspect could be clarified by e.g. analysis of 
radioactive metabolites in the heart at different time points, 
which may help to untangle the metabolic fate of the probe, or 
by inhibiting the different steps involved in the FAO process in 
order to gain mechanistic information about the in vivo behaviour 
of the new tracer.  
Conclusion 
In this study we have designed and developed a novel FAO PET 
tracer [18F]1, for potential application in cardiac imaging. We 
successfully prepared the precursors for the isotope 
incorporation and radiolabelled the tracer with tritium and 
fluorine-18. [18F]1 showed highly desirable preliminary features 
such as straightforward radiosynthesis and smooth automated 
preparation which could be easily translated in routine 
radiochemistry facilities. Last, but not least, preliminary in vivo 
results indicated rapid uptake from the bloodstream and 
excellent in vivo metabolic stability. The preclinical results 
confirmed the fast radioactivity clearance from the bloodstream 
and the good metabolic stability.  
Our working hypothesis was that [18F]1 would be metabolically 
trapped in the mitochondria, due to β-oxidation metabolism. 
However, the cardiac metabolism of FAs is a complex process, 
involving uptake and activation to corresponding fatty acyl-CoA, 
whose metabolic fate can be broadly distinguished between 
esterification to lipids or conversion to the corresponding 
carnitine derivatives by CPT-I for subsequent mitochondrial β-
oxidation. 
Unfortunately, kinetic analyses showed that the radiotracer 
uptake in the heart is subjected to dynamic equilibrium, rather 
than irreversible trapping. Moreover, the accumulation was not 
sensitive to CPT-I inhibition suggesting that its accumulation of 
[18F]1 was not associated with mitochondrial oxidative 
metabolism, which we hypothesised could be responsible for its 
metabolic trapping. Its retention in the heart may be due to other 
factors that would require further investigation. 
Nevertheless, the introduction of fluorine atoms in fatty acids 
showed potential to provide metabolic stability. Thus, this 
strategy could be used for the development of the next 




All reactions were carried out under nitrogen atmosphere and using dry 
solvents. Dry solvents were obtained from commercial sources and used 
without further purification. Reactions were monitored by thin-layer 
chromatography (TLC), unless otherwise noted. TLCs were performed on 
Merck silica gel glass plates (60 F254). Visualization was accomplished 
by UV light (254 nm) or staining with a ceric ammonium molybdate, 
KMnO4 and ninhydrin solution. Flash chromatography was performed 
using Silica gel (60 Å, particle size 40-63 μm) purchased from Merck. 1H 
NMR and 13C NMR spectra were recorded on a Bruker AVANCE III 400 
NMR spectrometer and calibrated using residual non deuterated solvent 
as internal reference. 19F NMR spectra were recorded on a Bruker 
AVANCE III 400 NMR spectrometer and were referenced to CFCl3. 13C 
NMR spectra were recorded with complete proton decoupling. Chemical 
shifts (δ) are reported in parts per million (ppm) and coupling constants 
(J) are given in Hertz (Hz). The following abbreviations are used for spin 
multiplicity: s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet-
doublet, dt = doublet-triplet, tt = triplet-triplet, m = multiplet, br = broad. 
When necessary, resonances were assigned using two-dimensional 
experiments (COSY and HSQC). Mass analyses were performed using 
Agilent 1200 HPLC system coupled to Agilent G6120 single quadrupole 
detector equipped with an electrospray ionization (ESI) source in direct 
infusion modality. ESI-MS spectra were recorded in positive mode, 
unless otherwise noted.  
10-Iododecan-1-ol (2) 
Compound synthesised according to the procedure reported by 
Karabiyikoglu et al.[41]  Sodium iodide (19.5 g, 129 mmol, 3.5 eq) was 
added to a solution of 10-bromodecan-1-ol (7.4 mL, 37 mmol, 1 eq) in 
acetone (100 mL) and the mixture was refluxed for 24 hours. The 
reaction mixture was cooled to room temperature, diluted with water and 
extracted with EtOAc. The combined organic layers were washed with 
1% Na2S2O3 aq. solution, brine and dried over Na2SO4. Filtration and 
concentration under reduced pressure followed by flash chromatography 
(8:2 hexane/EtOAc) afforded the known alcohol (9.3 g, 88%) as white 
solid. Spectroscopic data were in agreement with literature values[41]. Rf 
0.35 (8:2 hexane/EtOAc); 1H NMR (400 MHz, CDCl3): δ = 3.64 (t, J = 6.8 
Hz, 2H), 3.18 (t, J = 7.2 Hz, 2H), 1.81 (p, J = 7.2 Hz, 2H), 1.59-1.52 (m, 
2H), 1.39-1.29 (m, 12H) (OH signal was not observed). 
Dodec-11-en-1-ol (3) 
Compound synthesised according to the procedure reported by 
Karabiyikoglu et al.[41]  An oven-dried flask was charged with CuI (6.1 g, 
32.0 mmol, 1 eq). THF (40 mL) was added and the suspension was 
cooled to -40 °C. A solution of vinylmagnesium bromide in THF (1M, 96.1 
mL, 96.0 mmol, 3 eq) was added via cannula and the reaction was stirred 
for 15 minutes at -40 °C. Hexamethylphosphoramide (11.1 mL, 64.0 
mmol, 2 eq), triethyl phosphite (11 mL, 64.0 mmol, 2 eq) and a solution of 
2 (9.1 g, 32.0 mmol, 1 eq) in THF (50 mL) were then added sequentially 
dropwise via dropping funnel. The resulting mixture was stirred for 1 hour 
at -40 °C and allowed to warm to room temperature spontaneously 
overnight.  The reaction was quenched with sat. aq. NH4Cl solution (30 
mL) and extracted with EtOAc.  The organic layer was washed with brine 
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pressure followed by flash chromatography (9:1 hexane/Et2O) afforded 
the known colourless oil (4.60 g, 81%). Spectroscopic data were in 
agreement with literature values[41]. 1H NMR (400 MHz, CDCl3): δ = 5.81 
(ddt, J = 17.0 Hz, 10.2, 6.8 Hz, 1H), 4.99 (ddt, J = 17.0, 2.2, 1.6 Hz, 1H), 
4.92 (ddt, J = 10.2, 2.2, 1.2 Hz, 1H), 3.63 (t, J = 6.6 Hz, 2H), 2.06-2.00 
(m, 2H), 1.60-1.53 (m, 2H), 1.41-1.28 (m, 14H) (OH signal was not 
observed). 
12-Fluorododec-1-ene (4) 
DAST (6.7 mL, 4.99 mmol, 2 eq) was added to a solution of 3 (4.6 g, 
24.95 mmol, 1 eq) in DCM (50 mL) cooled to -30 °C.  The reaction was 
stirred 1 hour at -30 °C and allowed to warm to room temperature 
overnight. The reaction was cooled to 0 °C, carefully quenched with sat. 
aq. NaHCO3 solution (50 mL) and extracted with DCM. The organic layer 
was washed with brine, dried over Na2SO4 and concentrated under 
reduced pressure. Purification by flash chromatography (100% hexane to 
8:2 hexane/EtOAc) afforded the title olefin (2.3 g, 49%) as a colourless 
oil. Rf  0.50 (100% hexane); 1H NMR (400 MHz, CDCl3): δ = 5.81 (ddt, J 
= 17.1 ,10.2, 6.7 Hz, 1H), 4.99 ( ddt, J = 17.1, 2.1, 1.6 Hz, 1H), 4.92 (ddt, 
J = 10.2, 2.2, 1.2 Hz, 1H), 4.43 (dt, J = 47.5, 6.1 Hz, 2H), 2.10-1.98 (m, 
2H), 1.77-1.59 (m, 2H), 1.47-1.20 (m, 14H); 13C NMR (100 MHz, CDCl3): 
δ = 139.4, 114.2, 84.3 (d, J = 163.0 Hz), 34.0, 30.6 (d, J = 19.2 Hz), 29.6 
(3C), 29.4, 29.3, 29.1, 25.3 (d, J = 5.5 Hz); 19F NMR (376 MHz, CDCl3): δ 
-218.0 (tt, J = 47.5 Hz, 24.7 Hz, 1F). 
Ethyl 2,2,14-trifluorotetradec-3-enoate (5) 
Compound synthesised according to the methodology developed by 
Wang et al.[42] Acetonitrile (15 mL), CuI (144 mg, 0.755 mmol, 0.05 eq) 
and N,N,N′,N′′,N′′-Pentamethyldiethylenetriamine (PMDETA) (4.7 mL, 
22.7 mmol, 1.5 eq) were added into an oven-dried flask under nitrogen. 
The solution turned blue upon PMDETA addition. Ethyl 
bromodifluoroacetate (2.9 mL, 22.7 mmol, 1.5 eq) and a solution of 4 
(2.82 g, 15.1 mmol, 1 eq) in acetonitrile (15 mL) were then added 
dropwise via dropping funnel and the mixture was heated at 100 °C for 
12 hours. The reaction was filtered over celite washing with EtOAc and 
concentrated under reduced pressure. Purification by flash 
chromatography (95:5 hexane/EtOAc) afforded the title ester (3.81 g, 
82%) as colourless oil as a 5:1 mixture of E/Z isomers. (Z isomer 
resonances are denoted by an asterisk). Rf 0.4 (95:5 hexane/EtOAc); 1H 
NMR (400 MHz, CDCl3): δ = 6.32 – 6.20 (m, 1H), 5.97 - 5.87* (m, 0.2H), 
5.75 – 5.63 (m, 1H), 5.62 – 5.54* (m, 0.2H), 4.42 (dt, J  = 47.4 Hz, 6.2 Hz, 
2.4H), 4.31 (q, J = 7.1 Hz, 2.4H), 2.34 – 2.24* (m, 0.4H), 2.21 – 2.10 (m, 
2.2H), 1.79 – 1.62 (m, 2.4H), 1.49 – 1.25 (m, 20.4H); 13C NMR (100 MHz, 
CDCl3): δ 164.3 (t, J = 34.9 Hz), 142.5* (t, J = 7.1 Hz), 140.1 (t, J = 8.8), 
121.1 (t, J = 24.8 Hz), 121.0* (t, J = 26.2 Hz), 112.5 (t, J = 246.0 Hz), 
84.2 (d, J = 163.0 Hz), 63.0, 32.0, 30.5 (d, J = 19.3 Hz), 29.6, 29.5, 29.5*, 
29.4, 29.3, 29.2* (2C), 29.1, 28.5*, 28.2, 25.2 (d, J = 5.5 Hz), 14.1; 19F 
NMR (376 MHz, CDCl3): δ =  -98.8* (m, 0.4F), -102.9 (m, 2F), -218.0 (m, 
1.2F); MS (ESI, m/z): calcd. for C16H27F3O2Na [M+Na]+: 331.19, found 
330.9. 
2,2,14-Trifluorotetradec-3-en-1-ol (6) 
NaBH4 (690 mg, 18.1 mmol, 1.5 eq) was added portion wise to a solution 
of 5 (3.72 g, 12.0 mmol, 1 eq) in ethanol (40 mL) cooled to 0 °C and the 
reaction was stirred at room temperature. After 2 hours the reaction was 
cooled to 0 °C and quenched with sat. aq. NH4Cl solution. The mixture 
was extracted with EtOAc and the combined organic layers were washed 
with brine, dried over Na2SO4 and concentrated under reduced pressure. 
Purification by flash chromatography (8:2 hexane/EtoAc) afforded the title 
compound (3.1 g, 98%) as colourless oil as a 5:1 mixture of E/Z isomers. 
(Z isomer resonances are denoted by an asterisk). Rf 0.35 (8:2 
hexane/EtOAc); 1H NMR (400 MHz, CDCl3): δ = 6.23-6.11 (m, 1H), 5.90-
5.80* (m, 0.2H), 5.65-5.52 (m, 1H), 5.51-5.42* (m, 0.2H), 4.43 (dt, J  = 
47.4 Hz,  6.2 Hz, 2.4H), 3.83-3.70 (m, 2.4H), 2.31-2.20* (m, 0.4H), 2.18-
2.07 (m, 2H), 2.04-1.92 (m, 1.2H), 1.76-1.60 (m, 2.4H), 1.50-1.21 (m, 
17.2H); 13C NMR (100 MHz, CDCl3): δ 140.9* (t, J = 5.6 Hz), 138.6 (t, J = 
9.5 Hz), 122.2 (t, J = 25.4 Hz), 121.7* (t, J = 25.4 Hz), 120.4* (t, J = 239.4 
Hz), 119.5 (t, J = 237.8 Hz), 84.3 (d, J = 162.9 Hz), 65.2 (t, J = 32.5 Hz), 
32.1, 30.5 (d, J = 19.1 Hz), 29.6, 29.5, 29.4, 29.3, 29.2, 28.5, 25.1 (d, J = 
5.5 Hz); 19F NMR (376 MHz, CDCl3): δ -102.2* (m, 0.4F), -105.9 (m, 2F), 
-218.0 (m, 1.2F); MS (ESI, m/z): calcd. for C14H25F3ONa [M+Na]+: 289.19,  
found 289.1  
Ethyl 4,4,16-trifluoro-3-hydroxy-hexadec-5-enoate (8) 
Compound synthesised according to a modified reported procedure.[58,59] 
A solution of oxalyl chloride (1.0 mL, 11.49 mmol, 3 eq) in DCM (8 mL) 
was cooled to -50 °C and DMSO (1.6 mL, 22.9 mmol, 6 eq) was carefully 
added dropwise. The solution was vigorously stirred for 2 minutes at -
50 °C and then warmed to -30 °C. A solution of 6 (1.02 g, 3.83 mmol, 1 
eq) in DCM (10 mL) was then added dropwise via dropping funnel over 
10 minutes. The resulting mixture was stirred for additional 30 minutes at 
-30 °C, then TEA (6.4 mL, 45.96 mmol, 12 eq) was added dropwise via 
dropping funnel over 10 minutes. The reaction mixture was then stirred 
for additional 30 minutes at -30 °C and allowed to warm to room 
temperature in one hour via removal of the external cooling bath. The 
reaction was quenched with sat. aq. NH4Cl solution, diluted with water 
and extracted with DCM. The combined organic layers were washed with 
sat. aq. NaHCO3 solution, water, brine, dried over Na2SO4 and 
concentrated under reduced pressure to give the crude aldehyde as a 
yellow oil. The crude product 7 was used without further purification. Zinc 
dust (0.62 g, 9.55 mmol, 2.5 eq) was suspended in THF (12.5 mL) and 
the suspension stirred for 5 minutes. TMSCl (180 µL, 1.43 mmol, 0.375 
eq) was then added and the resulting mixture stirred for 15 minutes. The 
reaction was gently heated with a heat gun for 1 minutes under nitrogen 
flow and allowed to cool back to room temperature (three times). A 
solution of the freshly prepared aldehyde 7 (1.01 g, 3.82 mmol, 1 eq) in 
THF (10 mL) and ethyl bromoacetate (640 µL, 5.73 mmol, 1.5 eq) were 
consecutively added dropwise and the resulting suspension was refluxed 
for 1.5 hours. The reaction was quenched with sat. aq. NH4Cl solution, 
filtered over celite and extracted with Et2O. The combined organic layers 
were washed with water, brine, dried over Na2SO4 and concentrated 
under reduced pressure. Purification by flash chromatography (85:15 
hexane/EtOAc) afforded the title β-hydroxy-ester (590 mg, 44% over two 
steps) as a yellow oil as a 5:1 mixture of E/Z isomers. (Z isomer 
resonances are denoted by an asterisk). Rf = 0.5 [8:2 Hexane/EtOAc]; 1H 
NMR (400 MHz, CDCl3): δ = 6.25-6.10 (m, 1H), 5.93-5.82* (m, 0.2H), 
5.71-5.55 (m, 1H), 5.55-5.43* (m, 0.2H), 4.42 (dt, J = 47.4 Hz, 6.2 Hz, 
2.4H), 4.31-4.13 (m, 3.6H), 3.20-3.06 (m, 1.2H), 2.72-2.48 (m, 2.4H), 
2.33-2.21* (m, 0.4H), 2.19-2.06 (m, 2H), 1.78-1.57 (m, 2.4H), 1.50-1.22 
(m, 20.4H); 13C NMR (100 MHz, CDCl3): δ 171.7, 140.9* (t, J = 5.5 Hz), 
138.5 (t, J = 8.8 Hz), 121.3 (t, J = 24.6 Hz), 120.7* (t, J = 24.7 Hz), 120.5* 
(dd, J = 243.9 Hz, 241.7 Hz), 119.5 (dd, J = 241.9 Hz, 240.5 Hz), 84.2 (d, 
J = 163.0 Hz), 70.4 (dd, J = 31.8 Hz, 30.8 Hz), 62.1, 35.2 (t, J = 2.2 Hz), 
34.9* (t, J = 2.8 Hz), 32.0, 30.4 (d, J = 19.1 Hz), 29.4 (2C), 29.3, 29.2, 
29.1, 28.3, 25.1 (d, J = 5.5 Hz), 14.2; 19F NMR (376 MHz, CDCl3): δ -
101.3 – -102.2* (m, 0.2F), -105.0 – -105.8 (m, 1F), -106.3 – -107.1* (m, 
0.2F), -110.6 – -111.4 (m, 1F), -217.9 (m, 1.2F); MS (ESI, m/z): calcd. for 
C18H31F3O3Na [M+Na] +: 375.22, found 375.2; calcd. for C18H31F2O3 [M-
F]+: 333.22, found 333.2. 
Ethyl 4,4,16-trifluorohexadeca-2,5-dienoate (9) 
TEA (540 µL, 3.88 mmol, 2.5 eq) and MsCl (180 µL, 2.33 mmol, 1.5 eq) 
were added dropwise to a solution of 8 (546 mg, 1.55 mmol, 1 eq) in 
DCM (5 mL) cooled to 0 °C. The reaction was stirred for 12 hours at 
room temperature. The mixture was then cooled to 0 °C, DBU (460 µL, 
3.1 mmol, 2 eq) was added dropwise and the mixture was stirred for 2 
additional hours at room temperature. The reaction was quenched with 
sat. aq. NaHCO3 solution and extracted with DCM. The organic layer was 
washed with sat. aq. NaHCO3 solution and brine, dried over Na2SO4 and 
concentrated under reduced pressure.  Purification by flash 
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ester (300 mg, 58%) as a colourless oil as 5:1 mixture of E/Z isomers. (Z 
isomer resonances are denoted by an asterisk). Rf 0.4 (95:5 
hexane/EtOAc); 1H NMR (400 MHz, CDCl3): δ = 6.85 (dt, J = 15.8 Hz, 
10.3 Hz, 1.2H), 6.27 (dt, J = 15.8 Hz, 2.2 Hz, 1.2H), 6.18-6.07 (m, 1H), 
5.90-5.80* (m, 0.2H), 5.70-5.46 (m, 1.2H), 4.45 (dt, J = 47.4 Hz, 6.2 Hz, 
2.4H), 4.26 (q, J = 7.2 Hz, 2.4H), 2.26-2.17* (m, 0.4H), 2.17-2.07 (m, 2H), 
1.78-1.61 (m, 2.4H), 1.48-1.23 (m, 20.4H); 13C NMR (100 MHz, CDCl3): δ 
165.3, 140.4* (t, J = 7.2 Hz), 139.6* (t, J = 30.4 Hz), 139.5 (t, J = 30.0 Hz), 
138.5 (t, J = 8.8 Hz), 124.9 (t, J =7.9 Hz), 124.4* (t, J = 8.2 Hz), 123.7 (t, 
J = 27.9 Hz), 123.0* (t, J = 28.6 Hz), 117.4 (t, J = 234.0 Hz), 84.2 (d, J = 
163.0 Hz), 61.2, 32.0, 30.6 (d, J = 5.4 Hz), 29.6, 29.5, 29.4, 29.3, 29.2, 
28.4, 25.2 (d, J = 5.4 Hz), 14.2; 19F NMR (376 MHz, CDCl3): δ -90.11 — -
90.23* (m, 0.4F), -94.07 — -94.23 (m, 2F), -218.02 (m, 1.2F); MS (ESI, 
m/z): calcd. for C18H29F3O2Na [M+Na]+: 357.21, found 357.1; calcd. for 
C18H30F3O2 [M+H]+: 335.21, found 335.2 
Ethyl 4,4,16-trifluorohexadecanoate (9a) 
10% Pd/C (10 mg) was added to a degassed solution of 9 (83 mg, 0.25 
mmol) in methanol (1 mL); the round-bottom flask was purged with 
hydrogen and stirred overnight at room temperature. The reaction 
mixture was filtered over celite, concentrated under reduced and purified 
by flash chromatography (95:5 hexane/ EtOAc). The crude ester was 
used in the next step without further purification. An analytical sample 
was purified by preparative SFC using a Chiralpak IG column (250 x 20 
mm, 5 μm); mobile phase consisted of 10% MeOH\Formate 20 mM in 
CO2, 120 bar with an isocratic gradient and a flow of 70 mL\min. Rf  0.29 
(95:5 hexane/EtOAc); 1H NMR (500 MHz, CDCl3): δ 4.46 (dt, J = 47.4, 
6.2 Hz, 2H), 4.17 (q, J = 7.1 Hz, 2H), 2.54 (t, J = 2.4 Hz, 2H), 2.27 – 2.09 
(m, 2H), 1.91 – 1.78 (m, 2H), 1.77 – 1.65 (m 2H), 1.53 – 1.45 (m, 2H), 
1.45 – 1.18 (m, 19H); 13C NMR (126 MHz, CDCl3) δ 172.6, 124.4 (t, J = 
240.8 Hz), 84.3 (d, J = 163.9 Hz), 60.7, 36.7 (t, J = 25.0 Hz), 31.6 (t, J = 
25.9 Hz), 30.4 (d, J = 19.4 Hz), 29.6, 29.5, 29.4 (2C), 29.3, 29.3, 27.3 (t, 
J = 4.7 Hz), 25.2 (d, J = 5.6 Hz), 22.3 (d, J = 4.5 Hz), 14.2; 19F NMR (471 
MHz, CDCl3) δ -99.8 (p, J = 16.8 Hz, 2F), -218.0 (tt, J = 47.4, 24.9 Hz, 
1F); MS (ESI, m/z): calcd. for C18H33F2O2 [M-F]+: 319.24, found 319.3. 
Ethyl 4,4,16-trifluorohexadec-5-enoate (10) 
To a solution of (triphenylphosphine)copper hydride hexamer (Stryker’s 
reagent) (440 mg, 22.5 mmol, 0.3 eq) in toluene (5 mL) cooled to 0 °C 
was added a solution of 9 (250 mg, 74.9 mmol, 1 eq) in toluene (1 mL) 
dropwise. The red suspension was stirred for 12 hours at room 
temperature. After 12 hours further 0.3 equivalents of Stryker’s reagent 
were added and the suspension was stirred for additional 3 hours. The 
reaction was quenched by stirring at open air for 1 hour and 
subsequently filtered over celite. Purification by flash chromatography 
(95:5 hexane/ Et2O) afforded the title compound (130 mg, 52%) as a 
colourless oil as 5:1 mixture of E/Z isomers. (Z isomer resonances are 
denoted by an asterisk). Rf  0.2 (95:5 hexane/Et2O); 1H NMR (400 MHz, 
CDCl3): δ 6.13-6.00 (m, 1H), 5.78-5.68* (m, 0.2H), 5.59-5.35 (m, 1.2H), 
4.45 (dt, J = 47.4 Hz, 6.2 Hz, 2.4H), 4.14 (q, J = 1.8 Hz, 2.4H), 2.54-2.42 
(m, 2.4H), 2.34-2.16 (m, 2.8H), 2.13-2.03 (m, 2H), 1.76-1.57 (m, 2.4H), 
1.44-1.20 (m, 20.4H); 13C NMR (100 MHz, CDCl3): δ 172.5, 139.1* (t, J = 
6.2 Hz), 136.8 (t, J = 9.2 Hz), 124.6 (t, J = 26.2 Hz), 124.1* (t, J = 26.5 
Hz), 121.9* (t, J = 238.2 Hz), 120.9 (t, J = 236.4 Hz), 84.4 (d, J = 163.0 
Hz), 60.8, 33.8* (t, J = 27.5 Hz), 32.8 (t, J = 27.6 Hz), 31.9, 30.5 (d, J = 
19.2 Hz), 29.6, 29.5 (2C), 29.4 ,29.2, 28.6, 28.4*, 27.8 (t, J = 4.3 Hz), 
27.6* (t, J = 4.0 Hz), 25.3 (d, J = 5.4 Hz), 14.2; 19F NMR (376 MHz, 
CDCl3): δ -92.31 — -92.5* (m, 0.4F), -96.06 — -94.30 (m, 2F), -218.02 (m, 
1.2F); MS (ESI, m/z): calcd. for C18H31F3O2Na [M+Na]+: 359.23, found 
359.2; calcd. for C18H31F2O2 [M-F]+: 317.23, found 317.2. 
4,4,16-Trifluorohexadecanoic acid (1) 
To a solution of crude 9a (50 mg, 0.14 mmol, 1 eq) in THF\water 1:1 (1 
mL) was added lithium hydroxide (5 mg, 0.22 mmol, 1.5 eq) and the 
suspension was stirred overnight at room temperature. The mixture was 
acidified with HCl 1 N aqueous solution to pH 2 and extracted with 
EtOAc; the organic layer was dried over Na2SO4 and concentrated under 
reduced pressure. The crude acid was purified by preparative SFC using 
a Chiralpak IG column (250 x 20 mm, 5 μm); mobile phase consisted of 
10% MeOH\Formate 20 mM in CO2, 120 bar with an isocratic gradient 
and a flow of 70 mL\min.  The title compound (14 mg, 30%) was isolated 
as a white solid. Rf  0.2 (6:4 hexane/EtOAc); 1H NMR (500 MHz, CDCl3) δ 
4.46 (dt, J = 47.4, 6.2 Hz, 2H), 2.59 – 2.64 (m, 2H), 2.20 (tt, J = 16.6 Hz, 
7.8 Hz, 2H), 1.79 – 1.93 (m, 2H), 1.63 – 1.77 (m, 2H), 1.45 – 1.53 (m, 
2H), 1.38 – 1.44 (m, 2H), 1.25 – 1.37 (m, 14H); 13C NMR (126 MHz, 
CDCl3) δ 178.2, 124.2 (t, J = 240.8 Hz), 84.3 (d, J = 163.8 Hz), 36.7 (t, J 
= 24.9 Hz), 31.3 (t, J = 25.9 Hz), 30.4 (d, J = 19.3 Hz), 29.5 (2C), 29.4 
(2C), 29.3, 29.2, 27.0, 25.1 (d, J = 5.5 Hz), 22.3 (t, J = 4.5 Hz); 19F NMR 
(471 MHz, CDCl3) δ -100.0 (p, J = 16.7 Hz, 2F), -218.2 – -217.8 (tt, J = 
47.4, 24.9 Hz, 1F); MS (ESI, m/z): calcd. for C16H28F3O2 [M-H]-: 309.21, 
found 309.3. 
Dodec-11-enyl benzoate (11) 
To a solution of 3 (51 mg, 0.28 mmol, 1 eq) and DMAP (3.4 mg, 0.028 
mmol, 0.1 eq) in DCM (0.5 mL) were added pyridine (45 µL, 0.55 mmol, 2 
eq) and benzoyl chloride (48 µL, 0.42 mmol, 1.5 eq) at 0 °C dropwise; the 
reaction was stirred at room temperature. After one hour the reaction was 
quenched with sat. acq. NaHCO3 solution and the mixture was extracted 
with EtOAc; the organic layer was washed with sat. aq. NaHCO3 solution 
and brine, dried over Na2SO4 and concentrated under reduced pressure.  
Purification by flash chromatography (98:2 hexane/EtOAc) afforded the 
protected alcohol (80 mg, 88%) as colourless oil. Rf 0.35 (98:2 
hexane/EtOAc); 1H NMR (400 MHz, CDCl3): δ = 8.10-8.00 (m, 2H), 7.58 -
7.50 (m, 1H), 7.47-7.39 (m, 2H), 5.81 (ddt, J = 6.6 Hz, 10.3 Hz, 17.0 Hz, 
1H), 4.99 ( ddt, J = 17.1, 2.1, 1.6 Hz, 1H), 4.93 (ddt, J = 10.2, 2.2, 1.2 Hz, 
1H), 4.31(t, J = 6.7 Hz, 2H), 2.09-1.98 (m, 2H), 1.77 (p, J = 6.8 Hz, 2H), 
1.5-1.22 (m, 14H); 13C NMR (100 MHz, CDCl3): δ = 168.8, 139.3, 132.9, 
130.7, 129.7, 128.4, 114.2, 65.2, 33.9, 29.6 (3C), 29.4, 29.2, 29.0, 28.8, 
26.2; MS (ESI, m/z): calcd. for C19H28O2Na [M+Na]+: 311.21,  found 
311.2.  
[14-Ethoxy-13,13-difluoro-14-oxo-tetradec-11-enyl] benzoate (12) 
Compound synthesised according to the methodology developed by 
Wang et al.[42] Acetonitrile (33 mL), CuI (126 mg, 0.66 mmol, 0.05 eq) 
and PMDETA (4.1 mL, 19.8 mmol, 1.5 eq) were added into an oven-dried 
flask under nitrogen. The solution turned blue upon PMDETA addition. 
Ethyl bromodifluoroacetate (2.5 mL, 19.8 mmol, 1.5 eq) and a solution of 
11 (3.8 g, 13 mmol, 1 eq) in acetonitrile (5 mL) were then added 
dropwise via dropping funnel and the mixture was heated at 100 °C for 
12 hours. The reaction was filtered over celite washing with EtOAc and 
concentrated under reduced pressure. Purification by flash 
chromatography (9:1 hexane/EtOAc) afforded the title ester (5.4 g, 79%) 
as colourless oil as a 5:1 mixture of E/Z isomers. (Z isomer resonances 
are denoted by an asterisk). Rf 0.44 (9:1 hexane/EtOAc); 1H NMR (400 
MHz, CDCl3): δ =  8.08 – 8.01 (m, 2.4H), 7.59 – 7.50 (m, 1.2 H), 7.48 – 
7.39 (m, 2.4H), 6.33 – 6.20 (m, 1H), 6.07 – 5.78* (m, 0.2H), 5.73 – 5.61 
(m, 1H), 5.60 – 5.49* (m, 0.2H), 4.36 – 4.26 (m, 4.4H), 2.32 – 2.22* (m, 
0.4H), 2.19 – 2.07 (m, 2H), 1.75 (p, 2.4H), 1.52 – 1.15 (m, 20.4H); 13C 
NMR (100 MHz, CDCl3): 166.80, 164.4* (t, J = 35 Hz) , 164.3 (t, J = 34.8 
Hz), 142.5* (t, J = 7.1 Hz), 140.1 (t, J = 9.0 Hz), 132.9, 130.7, 129.7, 
128.4, 121.1 (t, J = 25.0 Hz), 121.0* (t, J = 26.4 Hz), 113.0* (t, J = 248.7 
Hz), 112.52 (t, J = 247.5 Hz), 65.2, 63.0, 32.0, 29.6, 29.5 (2C), 29.4 (2C), 
29.3*, 29.1, 28.8, 28.5*, 28.2, 26.1, 14.1; 19F NMR (376 MHz, CDCl3): δ = 
-98.8 – -98.9* (m, 0.4 F)), -102.8 – -103.0 (m, 2F)). MS (ESI, m/z): calcd. 
for C23H32FO4 [M-F]+: 391, found 391.23; calcd. for C23H32F2O4Na 
[M+Na]+: 433.23, found 433.2  
(14-Ethoxy-13,13-difluoro-14-oxo-tetradecyl) benzoate (13) 
10% Pd/C (100 mg) was added to a degassed solution of 12 (1 g) in THF 
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overnight at room temperature. The reaction mixture was filtered over 
celite and concentrated under pressure affording the title compound (1 g, 
quantitative) as a colourless oil. Rf 0.43 (9:1 hexane/EtOAc); 1H NMR 
(400 MHz, CDCl3): δ = 8.10-8.00 (m, 2H), 7.58 -7.50 (m, 1H), 7.47-7.39 
(m, 2H), 4.36-4.28 (m, 4H), 2.12-1.96 (m, 2H), 1.77 (p, J = 6.8 Hz, 2H), 
1.50-1.39 (m, 4H), 1.39-1.18 (m, 17H);  13C NMR (100 MHz, CDCl3): δ = 
166.8, 164.6 (t, J = 33.3 Hz), 132.9, 130.7, 129.7, 128.5, 116.6 (t, J = 
249.9 Hz), 65.3, 62.8, 34.6 (t, J = 23.3 Hz), 29.8, 29.7 (2C), 29.5, 29.4 
(2C), 29.2, 28.9, 26.2, 21.6 (t, J = 4.1 Hz), 14.1; 19F NMR (376 MHz, 
CDCl3): δ = -105.90 (t, J  = 16.9 Hz); MS (ESI, m/z): calcd. for 
C23H34F2O4Na [M+Na]+: 435.24, found 435.2.  
(13,13-Difluoro-14-hydroxy-tetradecyl) benzoate (14) 
Sodium borohydride (86 mg, 2.25 mmol, 1 eq) was added portion wise to 
a solution of 13 (930 mg, 2.25 mmol, 1 eq) in ethanol (10 mL) cooled to 
0 °C. After 1 hour of stirring at room temperature the reaction was 
quenched with sat. aq. NH4Cl solution and the mixture was extracted with 
EtOAc; the organic layer was washed with brine, dried over Na2SO4 and 
concentrated under reduced pressure. Purification by flash 
chromatography (8:2 hexane/EtOAc) afforded the title compound (765 
mg, 94%) as white solid. Rf 0.35 (8:2 hexane/EtOAc); 1H NMR (400 MHz, 
CDCl3): δ = 8.08-8.00 (m, 2H), 7.60 -7.51 (m, 1H), 7.48-7.39 (m, 2H), 
4.31 (t, J = 6.7 Hz, 2H), 3.73 (td, J = 12.8 Hz, 6.7 Hz, 2H), 1.98-1.82 (m, 
2H), 1.81-1.71 (p, J = 6.6 Hz, 2H), 1.59 (br s, 1H), 1.54-1.40 (m, 4H), 
1.40-1.19 (m, 14H);  13C NMR (100 MHz, CDCl3): δ = 166.9, 132.9, 130.7, 
129.7, 128.5, 123.5 (t, J  = 239.8 Hz), 65.3, 64.2 (t, J = 31.8 Hz), 33.4 (t, 
J = 23.8 Hz), 29.7, 29.5 (2C), 29.5 (3C), 29.4, 28.9, 26.2, 21.9 (t, J = 4.4 
Hz); 19F NMR (376 MHz, CDCl3): δ = -108.60 (tt, J  = 17.3 Hz, 12.7 Hz); 
MS (ESI, m/z): calcd. for C21H32F2O3Na [M+Na]+: 393.23, found 393.2; 
calcd. for C21H33F2O3 [M+H]+: 371.23, found 371.2. 
16-Ethoxy-13,13-difluoro-14-hydroxy-16-oxohexadecyl benzoate (15) 
Compound synthesised according to a modified reported procedure.[58,59] 
DMSO (2.4 mL, 33.4 mmol, 6 eq) in DCM (24 mL) was cooled to -78 °C, 
oxalyl chloride (1.5 mL, 16.7 mmol, 3 eq) was carefully added dropwise 
and the solution was vigorously stirred for 2 minutes at the same 
temperature. A solution of 14 (2.06 g, 5.56 mmol, 1 eq) in DCM (10 mL) 
was then added via dropping funnel over 10 minutes. The resulting 
mixture was vigorously stirred for one hour at -78 °C, before TEA (6.4 mL, 
45.96 mmol, 12 eq) was added via dropping funnel over 10 minutes. The 
reaction mixture was stirred for additional 30 minutes at -78 °C and 
allowed to warm to room temperature in one hour via removal of the 
external cooling bath. The reaction was quenched with sat. aq. NH4Cl 
solution, diluted with water and extracted with DCM. The combined 
organic layers were washed with sat. aq. NaHCO3 solution, water, brine, 
dried over Na2SO4 and concentrated under reduced pressure to give the 
crude aldehyde as a yellow oil. The crude product was used without 
further purification. Zinc dust (871 mg, 13.3 mmol, 2.5 eq) was 
suspended in THF (27 mL) and the suspension stirred for 5 minutes. 
TMSCl (250 µL, 2 mmol, 0.375 eq) was then added and the resulting 
mixture stirred for 15 minutes. The reaction was gently heated with the 
heat gun for 1 minute under nitrogen flow and allowed to cool back to 
room temperature (three times). A solution of the freshly prepared 
aldehyde (2.06 g, 5.3 mmol, 1 eq) in THF (10 mL) and ethyl 
bromoacetate (880 µL, 8.0 mmol, 1.5 eq) were consecutively dropwise 
added and the resulting suspension was refluxed for 1.5 hours. The 
reaction was quenched with sat. aq. NH4Cl solution, filtered over celite 
and extracted with Et2O. The combined organic layers were washed with 
water, brine, dried over Na2SO4 and concentrated under reduced 
pressure. Purification by flash chromatography (8:2 hexane/EtOAc) 
afforded the title β-hydroxy-ester (750 mg, 30% over two steps) as a 
yellow oil. Rf 0.35 (8:2 hexane/EtOAc); 1H NMR (400 MHz, CDCl3): δ = 
8.04 (dd, J = 8.4, 1.4 Hz, 2H), 7.55 (t, J = 7.4 Hz, 1H), 7.43 (t, J = 7.6 Hz, 
2H), 4.31 (t, J = 6.6 Hz, 2H), 4.24 – 4.08 (m, 3H), 3.34 (d, J = 5.3 Hz, 1H), 
2.70 (dd, J = 16.6, 3.1 Hz, 1H), 2.60 (dd, J = 16.7, 9.2 Hz, 1H), 2.03 – 
1.85 (m, 2H), 1.82 – 1.70 (m, 2H), 1.57 – 1.38 (m, 4H), 1.39 – 1.21 (m, 
17H); 13C NMR (100 MHz, CDCl3): δ = 172.5, 166.8, 132.9, 130.7, 129.7, 
128.4, 123.6 (dd, J = 246.9, 242.5 Hz), 69.4 (dd, J = 33.3, 27.3 Hz), 65.3, 
61.3, 34.6 (t, J = 3.3 Hz), 32.9 (t, J = 23.9 Hz), 29.7, 29.6 (3C), 29.5 (2C), 
29.4, 28.8, 26.2, 21.5 (dd, J = 6.0, 3.2 Hz), 14.2; 19F NMR (376 MHz, 
CDCl3): δ =  -109.0 – -110.3 (m, 1F), -113.4 – -114.6 (m, 1F); MS (ESI, 
m/z): calcd. for C25H38F2O5Na [M+Na]+: 479.27, found 479.3; calcd. for 
C25H39F2O5 [M+H]+: 457.27, found 457.3. 
[(E)-16-Ethoxy-13,13-difluoro-16-oxo-hexadec-14-enyl] benzoate 
(15a) 
TEA (93 µL, 0.67 mmol, 2.5 eq) and MsCl (31 µL, 0.40 mmol, 1.5 eq) 
were added dropwise to a solution of 15 (122 mg, 0.27 mmol, 1 eq) in 
DCM (1.2 mL) cooled to 0 °C. The reaction was stirred for 12 hours at 
room temperature. The mixture was then cooled 0 °C, DBU (80 µL, 0.53 
mmol, 2 eq) was added dropwise and the mixture was stirred for 2 
additional hours at room temperature. The reaction was quenched with 
sat. aq. NaHCO3 solution and extracted with DCM. The organic layer was 
washed with sat. aq. NaHCO3 solution and brine, dried over Na2SO4 and 
concentrated under reduced pressure.  Purification by flash 
chromatography (95:5 hexane/EtOAc) afforded the title α,β-unsaturated 
ester (92 mg, 78%) as a colourless oil. Rf 0.27 (95:5 hexane/EtOAc); 1H 
NMR (400 MHz, CDCl3): δ = 8.1 – 8.0 (m, 2H), 7.6 – 7.5 (m, 1H), 7.4 (dd, 
J = 8.3, 7.0 Hz, 2H), 6.8 (dt, J = 15.8, 11.3 Hz, 1H), 6.2 (dt, J = 15.8, 2.2 
Hz, 1H), 4.3 (t, J = 6.7 Hz, 2H), 4.2 (q, J = 7.1 Hz, 2H), 2.0 – 1.8 (m, 2H), 
1.8 – 1.7 (m, 2H), 1.5 – 1.4 (m, 4H), 1.4 – 1.2 (m, 17H); 13C NMR (100 
MHz, CDCl3): δ = 166.8, 165.3, 139.7 (t, J = 27.8 Hz), 132.9, 130.6, 
129.6, 128.4, 124.9 (t, J = 8.4 Hz), 120.8 (t, J = 239.6 Hz), 65.2, 61.2, 
37.2 (t, J = 25.6 Hz), 29.6 (3C), 29.5, 29.4 (2C), 29.3, 28.8, 26.1, 22.2 (t, 
J = 4.1 Hz), 14.3; 19F NMR (376 MHz, CDCl3): δ = -98.3 – -98.8 (m, 2F); 
MS (ESI, m/z): calcd. for C25H36F2O4Na [M+Na]+: 461.26, found 461.2; 
calcd. for C25H37F2O4 [M+H]+: 439.26, found 439.3. 
(16-Ethoxy-13,13-difluoro-16-oxo-hexadecyl) benzoate (16) 
10% Pd/C (6 mg) was added to a degassed solution of 15a (57 mg) in 
THF (1 mL); the reaction mixture was purged with hydrogen and stirred 
for 2 hours at room temperature. The reaction mixture was filtered over 
celite and concentrated under pressure affording the title compound (57 
mg, quantitative) as a colourless oil. Rf 0.39 (9:1 hexane/EtOAc); 1H NMR 
(400 MHz, CDCl3): δ = 8.07-7.99 (m, 2H), 7.58 -7.50 (m, 1H), 7.47-7.38 
(m, 2H), 4.31 (t, J = 6.7 Hz, 2H), 4.14 (q, J = 7.1 Hz, 2H),  2.50 (t, J = 7.6 
Hz, 2H), 2.25-2.08 (m, 2H),  1.89-1.70 (m, 4H), 1.51-1.39 (m, 4H), 1.39-
1.1 (m, 17H);  13C NMR (100 MHz, CDCl3): δ = 172.6, 166.8, 132.9, 
130.7, 129.6, 128.4, 124.5 (t, J = 239.1 Hz), 65.2, 60.8, 36.8 (t, J = 24.8 
Hz), 31.7 (t, J = 25.8 Hz), 29.7, 29.6 (3C), 29.5, 29.4 (2C), 28.8, 27.4 (t, J 
= 4.8 Hz), 26.2, 22.4 (t, J = 4.5 Hz), 14.3; 19F NMR (376 MHz, CDCl3): δ 
= -99.78 (p, J = 16.7 Hz); MS (ESI, m/z): calcd. for C25H38F2O4Na 
[M+Na]+: 463.27, found 463.2; calcd. for C25H39F2O4 [M+H]+: 441.27, 
found 441.3. 
Ethyl 4,4-difluoro-16-hydroxy-hexadecanoate (17) 
Sodium Ethoxide 21% in ethanol (44 µL, 0.12 mmol, 1.2 eq) was added 
dropwise to a solution of 16 (43 mg, 98 µmol, 1 eq) in ethanol (1 mL) 
cooled to 0 °C. After stirring for five hours at room temperature the 
reaction was quenched with sat. aq. NH4Cl solution and the mixture was 
extracted with EtOAc. The organic layer was washed with brine, dried 
over Na2SO4 and concentrated under reduced pressure.  Purification by 
flash chromatography (7:3 hexane/EtOAc) afforded the title compound 
(30 mg, 91%) as a white solid. (OH signal was not observed). Rf 0.36 
(7:3 hexane/EtOAc); 1H NMR (400 MHz, CDCl3): δ = 4.14 (q, J = 7.2 Hz, 
2H), 3.62 (t, J = 6.7 Hz, 2H),  2.50 (t, J = 7.5 Hz, 2H), 2.25-2.07 (m, 2H), 
1.90-1.72 (m, 2H), 1.63-1.51 (m, 2H), 1.51-1.40 (m, 4H), 1.38-1.16 (m, 
17H);  13C NMR (100 MHz, CDCl3): δ = 172.7, 124.5 (t, J = 239.2 Hz), 
63.2, 60.8, 36.8 (t, J = 24.8 Hz), 32.9, 31.7 (t, J = 25.8 Hz), 29.7 (2C), 
29.6, 29.5 (3C), 29.4, 27.4 (t, J = 4.8 Hz), 25.9, 22.4 (t, J = 4.5 Hz), 14.3; 
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calcd. for C18H34F2O3Na [M+Na]+: 359.25, found 359.2; calcd. for 
C18H35F2O3 [M+H]+: 337.25, found 337.3. 
Ethyl 4,4-difluoro-16-(tosyloxy)hexadecanoate (18) 
To a solution of 17 (438 mg, 1.30 mmol, 1 eq), DMAP (23 mg, 0.20 mmol, 
0.1 eq) and TEA (270 µL, 1.95 mmol, 1.5 eq) in DCM (3 mL) cooled to 
0 °C was dropwise added a solution of tosyl chloride (372 mg, 1.95 mmol, 
1.5 eq) in DCM (2 mL) and the reaction was stirred for 4 hours at room 
temperature. The reaction was quenched with sat. aq. NaHCO3 solution 
and extracted with DCM. The organic layer was washed with sat. aq. 
NaHCO3 solution, brine, dried over Na2SO4 and concentrated under 
reduced pressure.  Purification by flash chromatography (85:15 
hexane/EtOAc) afforded the title compound (610 mg, 96%) as a white 
solid. Rf 0.4 (8:2 hexane/EtOAc); 1H NMR (400 MHz, CDCl3): δ = 7.77 (d, 
J = 8.3 Hz, 2H), 7.33 (d, J = 8.0 Hz, 2H), 4.13 (q, J = 7.1 Hz, 2H), 4.00 (t, 
J = 6.5 Hz, 2H), 2.49 (d, J = 8.0 Hz, 2H), 2.43 (s, 3H), 2.24 – 2.07 (m, 
2H), 1.80 (q, J = 16.4 Hz, 2H), 1.61 (p, J = 6.6 Hz, 2H), 1.51 – 1.38 (m, 
2H), 1.33 – 1.17 (m, 19H); 13C NMR (100 MHz, CDCl3): δ = 172.6, 144.7, 
133.4, 129.9, 128.0, 124.5 (t, J = 240.8 Hz), 70.8, 60.8, 36.8 (t, J = 25.0 
Hz), 31.6 (t, J = 25.9 Hz), 29.6, 29.5 (2C), 29.4 (3C), 29.0, 28.9, 27.4 (t, J 
= 4.8 Hz), 25.4, 22.4, 22.3, 21.7, 14.3; 19F NMR (376 MHz, CDCl3): δ = -
99.8 (p, J = 16.8 Hz); MS (ESI, m/z): calcd. for C25H40F2O5SNa [M+Na]+: 
513.26, found 513.2; calcd. for C25H40FO5S [M-F]+: 471.26, found 471.2. 
Radiochemistry 
Labelling with tritium 
Tritium gas was obtained from RC Tritec (2.12 GBq/μmol, 1.06 
GBq/μatom) and was handled on a RC Tritec tritium manifold.  Analytical 
high-performance liquid chromatography (HPLC) was performed using a 
Waters Acquity HPLC system with in-line detection of radioactivity using 
a lab Logic BetaRam model 5. Liquid scintillation counting was performed 
with a Beckman LS 6500 scintillation counter. 
[3H]Ethyl 4,4,16-trifluorohexadecanoate ([3H]9a) 
Compound 10 (3 mg, 8.92 μmol) and 10% Pd/C (2 mg) were combined in 
THF (0.5 mL). The mixture was frozen using liquid nitrogen and the flask 
evacuated before closing the vacuum tap and being allowed to warm to 
RT. This was performed twice. The mixture was frozen once more and 
the flask evacuated, then tritium gas was released from the uranium bed 
by heating it with a blow torch. The mixture was allowed to warm to RT 
and stirred for 2 hours under tritium gas atmosphere (276.6 GBq). The 
solvent was removed under a nitrogen stream, the residue was diluted 
with 0.5 mL of ethanol and evaporated (repeated twice) to remove the 
labile tritium. The residue was diluted with ethanol, filtered (0.45 μm 
PTFE filter) and reconstituted in ethanol (30 mL) to give the crude 
product (30.9 GBq, radiochemical purity 83%). A portion of the crude (4 
GBq) were purified by reversed phase preparative HPLC: column 
XBridge BEH C18 OBD Prep Column, 130Å, 5 µm, 19 mm X 100 mm; 
solvents A water +0.1% TFA, B acetonitrile; gradient 70% B to 85% B in 
10 minutes; flow 10 mL/min. The purified fractions were dried under 
vacuum and reconstituted in 10 mL of ethanol to give the purified ester 
(1.5 GBq, radiochemical purity 98.6%) as a solution that was stored at -
20 °C. 
[3H]4,4,16-Trifluorohexadecanoic acid ([3H]1) 
To a solution of purified [3H]9a (725 MBq) in THF (100 μL) and water 
(100 μL) were added 100 microliters of a 10 mg/mL solution of lithium 
hydroxide in water (1 mg) and the reaction was stirred overnight at room 
temperature. Reaction was monitored by HPLC and finished after 12 h. 
The mixture was acidified with 100 microliters of HCl 1N, diluted with 
ACN and the solvent removed by rotary evaporation. The crude acid 
(495.7 MBq) was reconstituted in 10 mL of acetonitrile and purified by 
reversed phase preparative HPLC: column XBridge BEH C18 OBD Prep 
Column, 130Å, 5 µm, 19 mm X 250 mm; solvents A water +0.1% TFA, B 
acetonitrile; gradient 50% B to 100% B in 15 minutes; flow 10 mL/min. 
The purified fractions were dried under vacuum and reconstituted in 10 
mL of acetonitrile to give the purified acid (367 MBq, radiochemical purity 
> 99%.) as a solution that was stored at -20 °C. 3H NMR (533 MHz, 
CD3OD): δ = 1.84 (m, 0.05 T) 1.45 (m, 0.3 T), 1.25 (m, 1 T). 
Molar activity calculation 
The molar activity of the tritiated tracer was determined according to the 
protocol reported by Schenk et al.[48] Tritiated canagliflozin (molar activity 
1.3 GBq/mmol), synthesised by AstraZeneca, was used as internal 
standard in the NMR experiments. Its radiochemical purity was 91.71%, 
as determined by radio-HPLC. An NMR tube containing 100 MBq of 
tritiated canagliflozin and 100 MBq of [3H]1 dissolved in deuterated 
methanol was prepared and 1H/3H NMR spectra were acquired. 3H NMR-
based radioactive concentration of the analyte was calculated from the 
sum of the proton-decoupled tritium NMR integral for canagliflozin (7.18 
ppm 1.00 T, 6.76 ppm 0.98 T, sum 1.98 T) and [3H]1 (1.46 – 1.21 ppm, 
2.99 T). The analyte moles in the sample were determined using the 
aromatic canagliflozin proton integral (7.56 ppm, 2H) as standard, along 
with the analyte resonance of the methylene group bearing a primary 
fluoride (4.42 ppm, 1.47 H). The calculated [3H]1 radioactivity 
concentration was 44 MBq/mL and 0.05 µmol of analyte were found in 
the sample. The calculated molar radioactivity was 2730 GBq/mmol. 
Labelling with fluorine 
[18F]4,4,16-Trifluorohexadecanoic acid ([18F]1) 
The fluorine labelling was performed with a TRACERlab FXFN 
synthesiser (GE Healthcare). [18F]Fluoride was produced by proton 
irradiation of 18O-enriched water with 18MeV protons using a Cyclone 
18/9 cyclotron (IBA). After the end of bombardment (EOB), [18F]Fluoride 
was transferred into a ventilated and lead-shielded hot cell where it was 
trapped on a preconditioned Sep-Pak© Accell Plus QMA Plus Light 
cartridge (Waters, Milford, MA, USA) and eluted in the reaction vessel 
with 500 μL of a 7 mg/mL potassium carbonate solution in water; a 
solution of Kryptofix© 222 (15 mg) in acetonitrile (1 mL) was then added 
in the vessel. After azeotropic drying of the solvent, a solution of 
compound 18 (5 mg) in acetonitrile (300 μL) was added and the mixture 
was heated at 90 °C for 15 minutes. Afterwards, the vessel was cooled at 
room temperature before addition of KOH 0.2 N aqueous solution (180 
μL) and subsequent heating at 90 °C for 15 minutes. The reaction was 
then cooled at room temperature and the crude mixture was acidified 
with HCl 1 M aqueous solution (60 μL), diluted with a mixture of 
acetonitrile and water (7/3, 2 mL) and purified by reversed phase 
semipreparative HPLC: column Teknokroma Mediterranea Sea18, 5 μm, 
250 mm x 10 mm; solvents A water, B acetonitrile + 0.1% TFA; gradient 
70% B isocratic; flow rate 5 mL/min. The desired fraction (Rt = 15.8 min.) 
was collected, diluted with water (20 mL) and the radiotracer was trapped 
on a C18 cartridge (Sep-Pak© Light, Waters, Milford, MA, USA). The 
cartridge was washed with water (5 mL) before elution with ethanol (1 
mL) yielding the final radiotracer solution, which was diluted with 1% BSA 
in physiological saline solution (1:9, v:v) before injection into animals. 
Radiochemical purity and tracer identity were determined by HPLC, using 
an Agilent 1200 Series system equipped with a variable wavelength UV 
detector and a radioactivity detector (Gabi, Raytest). A Phenomenex 
Luna® C18 column (5 µm, C18, 100 Å, 250 x 4.6 mm) was used as the 
stationary phase and water (A)/acetonitrile containing 0.1% TFA (B) were 
used as the mobile phase, using the following gradient: 0 min 80% B; 20 
min 100% B; 23 min 100% B. The flow was set to 1 mL/min. Overall 
production time was typically 1 hour and 10 minutes from EOB and the 
radiochemical yields were in the range 10-15% decay corrected. 
Radiochemical purity was higher than 99%. Identity of the product was 
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In vitro metabolism 
Metabolism of [3H]1 was measured by incubating rat liver microsomes 
(0.1mg of protein; Thermo-Fisher Scientific) in a reaction mixture 
containing the labelled fatty acid (0.36 MBq; 13 nmol) in 0.12M 
potassium phosphate buffer pH 7.4. The enzymatic reaction was initiated 
by the addition of 10 μl freshly prepared 20 mM NADPH in 0.12M 
potassium phosphate buffer, pH 7.4.  At pre-selected time points (15, 30, 
60, and120 min), the reaction was terminated by the addition of 100 μl of 
acetonitrile. Samples were centrifuged at 5800 rpm for 5 min to pellet the 
precipitated protein. The resulting supernatants were analyzed by HPLC, 
using an Agilent 1200 Series chromatograph equipped with a multiple 
wavelength UV detector (λ = 254 nm) and radioactivity detector (Ramona, 
Raytest) equipped with an internal solid scintillation cell. HPLC conditions 
were the same as above for quality control.  
Animal experiments 
Drug challenge with etomoxir 
Animals were maintained and handled in accordance with the Guidelines 
for Accommodation and Care of Animals (European Convention for the 
Protection of Vertebrate Animals Used for Experimental and Other 
Scientific Purposes). All animal procedures were performed in 
accordance with the European Union Animal Directive (2010/63/EU). 
Experimental procedures were approved by (i) the internal ethical 
committee at CIC biomaGUNE; (ii) an accredited, external ethical 
committee (Órgano Habilitado del IIS Biodonostia); and (iii) local 
authorities (Diputación Foral de Guipuzcoa) (project code: PRO-AE-SS-
059). 
Blood clearance and in vivo metabolism were determined in rats 
(Sprague Dawley rats; weight between 188 g and 231 g; n=2). For 
imaging studies, animals (Sprague Dawley rats; weight between 188 g 
and 231 g; n=10) were fasted for 12 hours before imaging studies. After 
fasting, animals were divided in two groups called “Etomoxir” and 
“Control” (n=5 per group). In “etomoxir” group, rats received an 
intraperitoneal (I.P.) injection of etomoxir (Fluorochem; 40 mg/kg, 
solution in physiological saline solution containing 5% of DMSO; stored 
at 37°C) 2 hours before administration of [18F]1. Animals included in the 
“Control” group received an I.P. injection of an equivalent volume of 
vehicle at the same time point.  
 
PET imaging studies 
Animals were anesthetized by inhalation of isoflurane in pure oxygen (5% 
for induction; 1-2% for maintenance). The animal was positioned with the 
heart centred in the middle of the field of view of the PET scanner (β-
CUBE Molecubes preclinical platform), and the radiotracer (5.5-7.5 MBq; 
250-300 µL) was administered through the tail vein concomitantly with 
the start of image acquisition (60 min, list mode; effective field of view: 
10.5 cm). After finalising the PET imaging session, a whole-body CT 
scan (β-CUBE Molecubes preclinical platform) was acquired. PET data 
were reconstructed by 3D-OSEM iterative image reconstruction algorithm 
(30 iterations, with a reconstructed voxel size of 400 μm) and processed 
with PMOD (PMOD Technologies LLC) software analysis tool. The same 
software was used to co-register the PET and the CT images. Volumes 
of interest (VOIs) were drawn in the myocardium, liver, kidneys, lungs 
and cava vein. Dynamic TACs were obtained over the whole duration of 
the scan. 
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4,4,16-Trifluoropalmitate 1 was designed and synthesised as a novel metabolically trapped fatty acid oxidation PET imaging tracer for 
heart failure. The probe was radiolabelled with tritium and fluorine-18 and was evaluated in vitro as well as in vivo. [18F]1 showed fast 
clearance from the bloodstream and excellent metabolic stability, however it was not irreversibly trapped in the heart. 
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